Days af­ter an FDA ap­proval for its pso­ri­a­sis drug, Ar­cutis looks to raise $150M in pub­lic cap­i­tal

In this bear­ish mar­ket, pub­lic com­pa­nies have raced to in­vestors pri­mar­i­ly on­ly af­ter show­ing im­pres­sive clin­i­cal da­ta or reach­ing oth­er promi­nent mile­stones. And as the IPO win­dow re­mains shut, the newest com­pa­ny to hop on the band­wag­on is Ar­cutis Bio­ther­a­peu­tics.

The Cal­i­for­nia-based com­pa­ny an­nounced Thurs­day a pub­lic of­fer­ing of $150 mil­lion in shares of its com­mon stock. The news comes days af­ter Ar­cutis won FDA ap­proval for its phos­pho­di­esterase-4 (PDE4) in­hibitor rof­lu­mi­last, mar­ket­ed as Zo­ryve, in plaque pso­ri­a­sis for chil­dren and adults ages 12 and up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER